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Abstract
As the pivotal phase III randomized controlled clinical trial on
antithrombin concentrate in patients with severe sepsis did not
show a beneficial effect of antithrombin treatment on 28-day
mortality, the interest in the potential use of this treatment modality
in sepsis has diminished. However, recent data on the effect of
antithrombin administration on coagulation in combination with
recent analyses from the clinical trials that were aimed to restore
physiological anticoagulant pathways in patients with sepsis may
revitalize the interest in antithrombin concentrate for the treatment
of severe sepsis.
Introduction
Activation of inflammation and coagulation is important in the
pathogenesis of sepsis. Natural anticoagulant pathways have
a central position at the crossroads of coagulation and
inflammation pathways and the restoration of defective
anticoagulant pathways in patients with sepsis has, therefore,
received considerable attention. In this issue of Critical Care,
Kountchev  et al. [1] present some observations that may
revive interest in the use of antithrombin concentrate in
patients with severe sepsis. They show that six hours after the
bolus administration of antithrombin, plasma levels of
D-dimer, as a marker for the generation of fibrin, was lower in
virtually all patients. These data come on top of recent
additional analyses on the use of antithrombin concentrate in
patients with severe sepsis and may form a new foundation
for the further evaluation of this compound in prospective
clinical studies.
Antithrombin concentrate in sepsis
Antithrombin replacement therapy in patients with severe
sepsis and disseminated intravascular coagulation (DIC)
has been used since the 1980s. The rationale for this
adjunctive treatment strategy is based on the notion that
natural anticoagulant pathways are defective in patients
with a severe systemic inflammatory response upon
infection and that this may play a central role in the systemic
generation of thrombin and subsequent formation of micro-
thrombi, which may contribute to the pathogenesis of organ
dysfunction [2,3]. Indeed, plasma levels of antithrombin are
(very) low in patients with sepsis and are independent
predictors of the clinical outcome [4,5]. A substantial drop
in the level of circulating antithrombin has been demon-
strated to be a very early phenomenon in sepsis, lending
support to the idea that this protease inhibitor is involved in
the pathogenesis of the disease. In addition, experimental
studies suggest that antithrombin may not only have anti-
coagulant properties, but also may modulate inflammatory
responses [6]. Previous studies have shown that the strong
interaction between coagulation and inflammation may
indeed be a suitable point of impact for new adjunctive
strategies in patients with severe sepsis [7,8]. Antithrombin
concentrate has been evaluated in several small clinical
trials and aggregate results suggest at least a trend
towards a reduction in mortality [9]. A large randomized
controlled clinical trial in 2,314 patients with severe sepsis
(Kybersept trial), however, did not demonstrate a difference
between treatment with antithrombin for four days versus
placebo [10]. Interestingly, the subgroup of patients that
did not receive concomitant heparin (which was at the
discretion of the attending physician) had a clear trend
towards a better survival at 28 days, which was statistically
significant at 90 days. Of note, in the report by Kountchev
et al. [1], antithrombin-treated patients that received heparin
concomitantly had no improvement of the coagulation
derangement. Apparently, the combination of antithrombin
concentrate and administration of heparin does not work
out very well. Interestingly, this conclusion was already
suggested in the very first clinical trials of antithrombin in
patients with DIC 25 years ago, but may have been
forgotten over time [11].
Commentary
Antithrombin in sepsis revisited
Marcel Levi
Chairman of Medicine, Department of Vascular Medicine and Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, 
the Netherlands
Corresponding author: Marcel Levi, e-mail: m.m.levi@amc.uva.nl
Published online: 26 September 2005 Critical Care 2005, 9:624-625 (DOI 10.1186/cc3819)
This article is online at http://ccforum.com/content/9/6/624
© 2005 BioMed Central Ltd
See related research by Kountchev et al. in this issue [http://ccforum.com/content/9/6/R596]625
Available online http://ccforum.com/content/9/6/624
The importance of the anticoagulant effect of
antithrombin in sepsis
The decrease in D-dimer levels after the administration of
antithrombin to patients with severe sepsis as observed by
Kountchev et al. [1] may be of major significance. It should be
remembered that in the phase II dose-finding study of
recombinant human activated protein C in patients with
severe sepsis, which preceded the successful placebo-
controlled trial showing a survival benefit of this treatment, the
dose of activated protein C was based on the reduction in
D-dimer levels [12]. In addition, recent analyses of the
Kybersept database reveal that the presence of DIC is a
strong predictor of a beneficial effect of antithrombin. In fact,
patients that did not receive heparin and that had a positive
DIC score (according to the international scoring system
[13]) had a relative risk reduction for death of about 30%,
whereas patients that did not have DIC had no treatment
benefit. This finding is very reminiscent of data from the
phase III Prowess trial of recombinant human activated
protein C in patients with severe sepsis showing that patients
with DIC had a relatively larger reduction in mortality than
patients without DIC [14]. The findings of Koutchev et al. in
combination with the subgroup analyses from the Kybersept
trial and the experience with recombinant human activated
protein C may indicate that, for selected patients with severe
sepsis, administration of antithrombin concentrate may be
beneficial. This hypothesis, however, obviously needs
prospective confirmation in a properly designed randomized
controlled clinical trial. The odds of finding a successful result
by administering antithrombin to patients with severe sepsis
in such a trial may be greatly improved by the recent insights
mentioned above and would evidently have a potentially major
impact on the treatment of patients with severe sepsis.
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